The Milk Factor Appropriately the first investigation undertaken in the field of breast cancer was into etiology. During the 1940s the seminal work of J J Bittner on the etiology of murine mammary cancer was being widely discussed. No one in this audience will need to be reminded that Bittner found that ifhe took weanling mice from a mother of a high cancer strain and passed these to a foster-mother from a strain which did not naturally develop breast cancer, then these weanling mice, when they grew up, exhibited the same behaviour in relation to breast cancer as was natural to their foster-mother. Conversely, if weanling mice of a low cancer strain were put to suckle with a foster-mother of a high cancer strain, then these mice, when they grew up, developed breast cancer to the high degree 277 9
It is a great privilege to have been invited to deliver the inaugural Leah Lederman Lecture but I have grave forebodings that the quality of this lecture will not compare with the outstanding contributions which I know will follow in future years.
My qualifications, such as they are, for addressing the Section of Oncology derive, I suppose, from the fact that in 1936 I started a breast clinic at Guy's Hospital and , except between 1941 and 1946, 1 have devoted much of my professional life during the succeeding 37 years to a study of breast disease and, apart from fibroadenosis and mammillary fistula, especially to breast cancer. As a clinician my knowledge of the subject is naturally circumscribed and I can claim no more than a routine acquaintance with the sciences of pathology, immunology, radiotherapy, chemotherapy and the disciplines ancillary to the understanding and management of breast cancer. In 1936 the clinic was held on one afternoon in the week. It usually lasted about one and a half to two hours, and half-a-dozen patients were seen by me and my secretary working unaided. Now six clinics are held in the week, each lasting up to four hours, and at every clinic about 50 patients are seen. The number of qualified doctors working whole-time in the clinic is four and they have an adequate supporting staff of secretaries and technicians. By this year over 12500 patients will have passed through what is now termed the Breast Unit, and approximately half of them are suffering or have suffered from malignant disease. Furthermore, the Department of Health and Social Security has built a special unit at New Cross where the bulk of inpatient work is now performed; outpatients are still seen at Guy's. If this is a success story, and 1 believe it is, the success is very largely due to my colleague John Hayward who joined me in 1953 and has worked -indefatigably and exclusively on the problems of breast cancer. It was he who persuaded the Department of Health to give us a purpose-built unit; it was he who designed it and, perhaps most important of all, it was he who forged the links with the Imperial Cancer Research Fund so that joint projects with R D Bulbrook were launched in the fields of hormone assay and projective diagnosis which are of present value and promise exciting possibilities for the future. I am happy to say that when I retired John Hayward became the director of the unit.
I believe the unit, as I must learn to call it, has made some impact in the fields of the study of breast cancer; whether it has made any advances and, if any, how important these advances are, only the future will tell. Looking back over nearly forty years, certain facets of our work stand out as leading perhaps to new ways of thinking about some of the problems, and it is therefore of these that I wish to speak. natural to their foster-mother. The explanation of this phenomenon was found to consist in a factor-the Bittner factor or the milk factorwhich was contained in, or was absent from, the mother's milk and which determined whether or not breast cancer would develop in the offspring in later life. This factor has been characterized as a virus-like body and appears to have every ultramicroscopical, chemical, and physical property exhibited by a virus. This was such an important concept that it seemed worth while mounting a long-term investigation to see whether a similar state of affairs operated in the human. Accordingly 1500 newborn girls who had never received human milk and therefore could not have received the human milk factor if there were one, were matched with 1500 girls born within three months of their matching partners and in the same district, who had received human milk. Complicating factors such as the possibility of the passage of the factor to the fetus via the semen of the male parent, and the duration of lactation were ignored. The investigation was a straightforward question as to whether the ingestion of human milk in any quantity might influence the liability to develop breast cancer many years later in the human, as the ingestion of the milk of certain murine strains certainly did in the mouse.
At first these two populations were contacted through their parents at regular intervals and a study was made to see whether the babies fed on human milk developed diseases common to children with greater or less frequency than the babies who had never received human milk. Or put more scientifically, could the proposition be confirmed that the human infant is born immunologically competent, receiving its immunoglobulins entirely through the placenta, or does part of this competency derive from the colostrum as it does in certain animals, notably the calf? The findings on 1068 children showed that there was no immunological advantage in the ingestion of human milk, the two populations behaving in a strikingly similar way both in regard to the percentages that developed chicken pox, whoopingcough, measles, German measles and scarlet fever and also to the age at which these diseases appeared. If there were need to confirm it, the permeability of the human placenta to immunoglobulin was thus confirmed (Atkins 1958) .
As these 3000 girls grew up, married and moved away from their homes it became impossible to keep in contact with them, but with the enthusiastic cooperation of those in charge of the national records at Southport, especially Mr D J Smale, every one of these individuals is documented and a special arrangement has been made whereby once a year any deaths that have occurred are reported and a copy of the death certificate is forwarded to the Breast Unit at Guy's. Of the 1500 in each of the two contrasted populations we would expect 50 cases of breast cancer to develop. Of the 50, 25 in each group would probably die of the disease and breast cancer would be recorded as a cause of death in at least 20 of those.
One might assume that with such small numbers it was hardly worth while to pursue the study, but fresh investigation on the milk of women from families with a high incidence of breast cancer is highly suggestive that their milk is abnormal in a specific way; this makes the pursuit of the inquiry, which operates automatically with very little trouble to anyone, of some consequence.
Dischargefrom the Nipple
The next investigation which I would like to describe, taking them in logical order rather than in the order in which they were conducted, was in the management of discharges from the nipple, a symptom which must in many cases carry with it the suspicion of a malignant cause.
We have now dealt with over 500 such cases and certain interesting features have emerged. We have had no case where cancer has been the cause of the discharge unless this discharge has given a positive test for heemoglobin or one of its breakdown products. Even where the discharge does give a positive test for hwmoglobin, the chances that this heamoglobin-laden discharge is due to cancer is very slight in patients under the age of 40 (2 cases only).
These findings, coupled with the elaboration of the operation that we named (not very euphoniously as it appears to me now) 'microdochectomy', enabled us to derive a plan which we drew up in 1963 and which was published the following year by the late Brigitte Wolff and myself (Atkins & Wolff 1964) , dealing with our first 303 cases; we have not had occasion to modify our plan in the light of subsequent experience.
First let me outline in general terms the operation of microdochtectomy. The idea is to remove the duct from which the discharge is emanating, together with its tributaries and major ductules, with minimal disturbance to the rest of the breast. Obviously this can only be done if the discharge is coming from one duct, as it usually is, and if this duct orifice can be identified. I myself use, and have always used binocular loupes, but my younger and less myopic assistants seem able to dispense with this aid.
The duct orifice is identified (Fig 1) and the duct cannulated with a blunted fine cambric needle, the eye then being stitched with finest silk to a piece of skin immediately adjacent to the orifice (Fig 2) . The whole nipple is then distended with saline to which a little adrenalin has been added so that it is completely blanched and should be almost bloodless. The skin around the needle and the stitch is circumcised and flaps are raised (Fig 3) . The duct and its tributaries are then dissected for a distance of 3-4 cm. At this distance from the orifice it will not be possible to trace individual tributaries so that a piece of tissue is then excised in the depth of the breast producing a specimen (Fig 4) of sufficient quantity to reveal the pathology. The assumption made, which in our experience has almost invariably been justified, is that if a diseased area produces a substance which can find its way to the orifice of a duct it is situated within this degree of proximity to the surface; I need not deal here with the slight additional dissection required if, on examination of the depth of the wound, this appears not to be the case.
Armed with these findings and with this tool we have evolved the plan shown in Fig 5. You may well ask the fate of the two women under the age of 40 who had a hmmoglobin-laden discharge, but who were kept under observation. These two patients later developed a lump which was dealt with according to classical teaching, namely by excision, frozen section to confirm the malignancy, and in these cases, by simple mastectomy. Both, as we should expect, because a cancer which declares itself by a blood-stained discharge from the nipple is almost invariably of low malignancy, are alive many years after the operation, without signs of recurrence.
The Early Case
The next investigation which it is logical to describe, although in fact it is the latest upon which we embarked, concerns itself with the treatment of early breast cancer. Before doing this, however, we must agree with the aphorism that has over the years become almost the motto of the Breast Unit, that 'no lady has a lump in the breast'; by which we mean that if a lump (as opposed to a diffuse nodularity) is felt, then this lump must be exorcised in one way or another.
If it is cystic it is aspirated; if this causes the lump to disappear and it does not recur, and if the aspirated fluid gives a negative test for hiemoglobin (whatever its colour), then apart from periodic inspection this is all that need be done. Very occasionally puncture of the cyst may cause a little blood to leak into the cyst, but this complication was not met with in this series. If the lump is solid it is excised. If it is not quite certain whether the lump is cystic or solid, then the patient is admitted to hospital, warned about the possibility of an operation, prepared for one and, at the appropriate time, placed on the' operating table. Attempts are then made to aspirate the lump; if this is successful the patient is forthwith, in the words of Sir Astley Cooper, 'returned with delighted affection to the bosom of her family'; if attempts at aspiration are unsuccessful, the aniesthetic for which she has been prepared is administered and the lump is excised and subjected to frozen section.
In this way we are dealing now with patients on whom the diagnosis of cancer has been made without peradventure and it is with this population that our investigation was concerned.
For the whole of this century, until the last two decades, to perform radical mastectomy has been the accepted doctrine in the treatment of early cancer of the breast. After all, to remove in one block the organ affected, together with those readily accessible lymph nodes which drain that organ, seems a most sensible thing to do when confronted by a cancer which commonly spreads by the lymphatic system. Unfortunately this concept pays no heed to the immunological reaction of the body to cancer, and it demands an operation which may remove those very structures upon which the defence to local spread may depend; and, by its magnitude, the operation may so damage the humoral immunological mechanism of the body that more harm might be done than good. Nor does it allow for the distressing frequency, as we now appreciate, of skeletal The question which we decided to investigate was whether, in early cancer of the breast, an operation less mutilating than radical mastectomy might be equally effective in saving life. The operation which we chose was wide excision of the lump; we steadfastly refused to call it 'lumpectomy', but with the assistance-of Dr W J Mann we named it extended 'tylectomy', which was the most euphonious word of exclusively Greek derivation which matched the circumstances, if we accept that a lump of cancer in the breast can be described as a node or nodule.
Before embarking on a trial to compare extended tylectomy with radical mastectomy in the treatment of early breast cancer, ethical considerations obtruded as they do in all clinical trials, but in this instance to a degree which demanded exceptionally careful attention.
I shall not dwell on all the consultations which took place in regard to this matter except to observe that we have one rule: that if we would allow a member of our own family to enter a trial it is ethical, if not, as the philosophers say, not. Moreover, it is not sufficient that one of our team should be so minded; we must all agree and be prepared to stand by that agreement if, as it turned out, a member of our family was so circumstanced.
In 1955 we had considered mounting such a trial, but this ethical rule prevented us. However, in the ensuing five years so much evidence of a practical nature had accumulated that, still in observance of our rule, it seemed not only ethical Table 2 Technique for tylectomy cases (1) Excision of lump with surrounding breast tissue within 3 cm
(2) Synoperative thioTEPA as for radical
(3) Postoperative radiotherapy 3800 rad over three weeks by linear accelerator to glancing field including breast and internal mammary chain. 3000 rad over two weeks to axilla and supraclavicular fossa Table 3 Technique for radical mastectomy cases (1) Radical mastectomy (2) Synoperative thioTEPA 2 mg per stone (6.3 kg) bodyweight with premedication 1.5 mg per stone bodyweight on 2nd postoperative day 1 mg per stone bodyweight on 4th postoperative day (3) Postoperative radiotherapy 3000 rad over 3 weeks to internal mammary, supraclavicular and axillary fields but mandatory that such a trial should be undertaken. The nature of this evidence is not essential to the argument but it depended upon the experience of radiotherapists treating patients who had a lump removed from the breast which only after some delay had been diagnosed as cancer; from surgeons who in certain, though not strictly specified cases, had performed only excision of the lump followed by radiotherapy; from a follow up of some 300 cases of cancer of the breast treated in New South Wales (Fleming & Wilkinson 1961) ; from the evidence of the Oncological Institute in Moscow where limited excision and hormone therapy was freely practised; and a number of other pieces of evidence, all tending to show that patients who had been subjected to something less than radical mastectomy and sometimes something much less, like tylectomy, did surprisingly well.
So the trial was mounted in 1961. The subjects were all patients over the age of 50 with operable breast cancer (Manchester stages 1 and 2) who were judged suitable for radical mastectomy. Exceptions are listed in Table 1 . Patients were assigned by random selection to the two treatment groups and the techniques are set out in Tables 2 and 3. In such a trial it was obviously important to monitor the responses to these two contrasted treatments almost continuously so that the trial could be stopped at once should any disadvantage appear to accrue to the one or the other of the two groups. An analysis of the results five years after the trial had started showed no difference in the survival rate between the two groups. At the time we had not sufficient material to analyse clinically Stage 1 and clinically Stage 2 cases separately with any meaningful result, but by 1971 after ten years we had, and our findings were of the greatest interest.
A survival curve drawn at that time (Fig 6) , taking Stages 1 and 2 together in the 370 patients who had entered the trial, showed no significant difference in the response to treatment between the two groups. But when these curves were drawn separating the patients into clinical Stage 1 cases and clinical Stage 2 cases (Fig 7) , a significant difference in favour ofradical mastectomy for Stage 2 patients was revealed. The balancing advantage to Stage 1 patients treated by tylectomy which tended to mask the effect on Stage 2 cases when the two were grouped together did not reach a level of statistical significance.
For this reason the trial on Stage 2 patients has now been terminated and they are at present subjected to radical mastectomy. The trial will continue on Stage 1 patients until it can be shown that there is no difference in regard to life expectancy between these two operations, in which case the less mutilating operation will be chosen; or alternatively that one of the two treatments shows a significant advantage over the other; in which case that treatment will be advocated.
Following the publication of our paper (Atkins et al. 1972 ), a brisk correspondence took place informing us that our dosage of radiotherapy was ill-conceived, that our statistical methods were unsatisfactory (although we had all through received the most highly qualified counsel), that we were investigating the wrong things, and so on. Some of this criticism was sensible, some was highly charged with emotion, but it was all carefully considered; and the only conclusion which we came to was that it was a mistake to submit a piece of work on such a contentious matter to ajournal with a correspondence column. One interesting point picked up in discussions following the publication of our paper was the unreliability of using clinical staging. This course was inevitable in our trial, for in the tylectomy group pathological staging was not available. We had to declare that the error in our clinical staging, as corrected by pathological staging in our Stage 2 cases, was about 25 % in both directions. However, pathological staging is itself by no means exempt from error, although in one direction only: a negative pathological report.on the lymph nodes does not mean that there are no cancer cells there. At one time we employed a histologist, Miss Brigitte Wolff, whose contribution to the paper on discharges from the nipple has already been mentioned; she spent far more time than it would be possible to devote in a routine laboratory to the study of our radical mastectomy specimens, so that our five-year survival rate on Stage 2 cases turned out to be much better than, I believe, any other published results. Of course our Stage 2 cases contained many specimens which would have been classed as Stage 1 after a routine examination of the axillary nodes, and we forebore to publish these results, indeed until now even to mention them.
It may well be that the important point is not whether there are any cancer cells in the lymph nodes (theoretically pathological Stage 2), but how many of these there are. If the population of cancer cells is modest and cannot be detected clinically then the immune mechanism may still be intact and it might be meddlesome to remove the nodes. If, on the other hand, the population is so considerable as to be clinically appreciated, then there may be more likelihood that the local immune mechanism has been overwhelmed and that the lymph nodes are acting only as a reservoir for dissemination, and had better be removed. This would seem to be a reasonable explanation of our results, and it places the responsibility for deciding on treatment squarely on the shoulders of the clinician.
With all this uncertainty, how should the practising surgeon, not equipped to conduct trials, deal with the commonly encountered problem of early breast cancer? We must declare that nobody knows what is the best method of treatment in these cases and only the prosecution of more clinical trials contrasting the value of the many commonly practised methods will lead to any advance in our knowledge. Perhaps by the time this tangle is sorted out the matter will be of historical interest only and treatment will be by hormones or by immunological methods.
However, in the meanwhile something must be done and in the light of our present knowledge, I should myself practise the following plan. First' where these are available, the most sophisticated methods of bone scanning should be used to detect any skeletal secondaries not revealed by standard radiological studies. The patient should be examined by a doctor experienced in deciding whether the growth is Stage 1 or Stage 2; experienced, that is, in assessing whether axillary lymph nodes, which are generally palpable, are invaded by more than a trivial number of cancer cells, in the TNM classification NO or Nla. I adhere to the principle that orthodox treatment should be practised until something is shown significantly to be better, but if the case is regarded as Stage 1 and the breast is large I would expect that extended tylectomy followed by routine radiotherapy to the remains of the breast, the axilla, the internal mammary chain and the supraclavicular fossa will shortly be shown to be the method of choice. If the breast is small, tylectomy is more disfiguring than simple mastectomy, which would then be preferred. In Stage 2 cases I would recommend radical mastectomy followed by radiotherapy to the axilla, internal mammary chain and supraclavicular fossa.
Whether or not radiotherapy should be given in either instance is hotly debated, and the question can only be resolved by further trials; but the matter is even more complicated because the results of a trial -with or without radiotherapyusing the technique of one radiotherapist may properly be challenged by a radiotherapist using another.
The Intermediate Case
We may now consider the treatment of a case of intermediate severity, in which the cancer is confined to the breast and its glandular field but for one reason or another is inoperable (Manchester Stage 3). These cases are treated by radiotherapy and it may so happen that the effect of radiotherapy is to reduce the clinical presentation to a state where, if the case had been first seen in that condition and no radiotherapy had been given, it would have been deemed operable. Some thirty years ago it would have been regarded as quite improper, if not disastrous, to approach such a case with the knife. The danger of cutting into cancerous tissue and disseminating it widely was held to be very grave and it was agreed that relatively well should be left alone. In fact there was no evidence that this was so and the possibility was suppositious. We therefore mounted a trial with patients who, as a result ofradiotherapy, had been reduced from Stage 3 to Stage 2 or even Stage 1. These patients were divided by random selection into two groups. One group was treated by radical mastectomy; the other was kept under observation and surgical treatment was offered only when some unendurable complication, like fungation of the breast,ensued. The result of this trial showed that there was no significant difference in the mortality rate, whatever was done. The survival curves (Fig 8) are as nearly as possible identical and indicate that the surgeon has a free hand to make the patient as comfortable physically and as free from anxiety psychologically as his skills allow.
The Late Case, Adrenalectomy and Hypophysectomy Our most constant preoccupation, indeed our first trial, was concerned with the late case. We have conducted no trials concerning the relative merits of different hormones by administration, nor on the effects of chemotherapy, because many other centres are engaged on this type of investigation, but our organization was such that one particular trial was peculiarly well adapted to our circumstances, or so we thought. In 1947 we had performed five subtotal adrenalectomies at a time when there was no adequate replacement therapy and the results were not satisfactory. The right adrenal was removed and a variable amount of the left, the bleeding from the cut surface of the glandular stump being controlled by diathermy, so that there was no means of telling how much of the remaining adrenal had in fact been destroyed. We found that if the removal of adrenal tissue was adequate to affect the widely disseminated growth, the patient died ofadrenal insufficiency.
In 1953 cortisone was available as replacement therapy and the operation of bilateral total adrenalectomy was introduced by Charles Huggins in Chicago. We therefore followed his lead and practised this operation on all those cases of disseminated breast cancer for which nothing else could be done. At about the same time Luft and Olivecrona in Stockholm introduced the operation of hypophysectomy for precisely the same type of case and this operation was adopted and performed with the greatest skill by my colleague Murray Falconer and later by Peter Schurr.
For a time at the Breast Unit whether the patient was subjected to adrenalectomy or hypophysectomy depended only on whether she happened to have been sent to Murray Falconer or to me. This demanded a controlled clinical trial, the first we embarked upon, which started in 1954.
By 1957 we were able to report on our first 60 randomized cases. The results were equivocal although there appeared to be some advantage to hypophysectomy both in regard to immediate mortality and, excluding these deaths, to the period of survival. This advantage, although far from being statistically significant in regard to the features we used for measurement, of which the most emphatic were the early and late mortality rates, were nevertheless sufficiently disturbing for us to be worried about the ethics of continuing the trial. Each of us, at this time, would have hoped that, had a member of our own family been concerned, the ticket drawn out of the box would read 'hypophysectomy' rather than 'adrenalectomy', thus contravening our one rule of ethics. I therefore called on Sir Austin Bradford Hill to seek his advice, and he gave us' a rule which we have followed ever since in the many trials which we have undertaken: namely, that if a trial was ethical in the first place it would be qilite unethical to terminate it until a meaningful result had been achieved. This, of course, left the definition of 'meaningful' to be decided upon and it is only from the experience of the last twenty years that we have been able to interpret this term to our satisfaction. If the issue is one of life and death, then the level of probability which would be acceptable should be interpreted liberally and a statistical probability of 0.05 in favour of one method of treatment rather than the other could be regarded as 'meaningful' and the trial would be terminated. The treatment with a 20 to 1 chance of being the better should be preferred. If on the other hand the issue depended upon a few weeks more of survival of a gravely ill and incapacitated patient, then a far more rigorous standard of probability should be enjoined, up to a p value of 0.01, before it would be prudent to terminate the trial; the result would not be so important, but by then the evidence for its preference far more secure.
Thus we returned to our trial, and not many months had passed before we could claim (Atkins Table 4 Deaths after adrenalectomy and hypophysectomy (Atkins et al. 1960 No. ofdeaths No. of 0-20 21days-03 patients days 3 months months Adrenalectomy 79 7 19 26
Hypophysectomy 70 3 10 13 Table 5 Comparison of results for patients surviving 20 days from start of operation (Atkins et al. 1960) Adrenalectomy (Tables 4 & 5) . As Sir Austin said, if we had terminated our trial when we first consulted him half our patients would have received an inferior treatment and we would never have known which half.
Another complication of controlled clinical trials was, however, revealed by this, our first essay. It was true that in the circumstances then prevailing at the Breast Unit with its superb neurosurgical service, hypophysectomy was the treatment of choice. But what of the other centres throughout the world? Had we published our results without emphasizing this particular and, at that time peculiar advantage, we would have run the risk of extolling the virtues of an operation which only a highly skilled and experienced neurosurgeon can perform without disaster, instead of an operation which any trained surgeon can perform competently and which is only a little, though statistically significantly, less effective.
Determinance
When I say that adrenalectomy was only 'a little' less effective than hypophysectomy, what do I mean? The difference in effectiveness as measured by mortality rates was 'significant' and eventually 'highly significant'. We came to realize as we studied the material from various trials that in the less scientifically sophisticated circles of clinical medicine a source of considerable misunderstanding had arisen from the arrogation by the statistician of the words 'significant' and 'significance' to mean something quite different from what they were ordinarily held to mean. This term as used by the statistician simply measures the confidence which can be attached to a statement, that it is almost certainly true (probability a hundred to one or more), that it is likely to be true (probability about twenty to one), or that no reliance whatever can be placed upon it. When applied to a controlled clinical trial therefore, to state that one treatment is better than another and that this difference is highly significant gives no indication of the degree of difference, which may be all-important.
In the instance of our adrenalectomy-hypophysectomy trial the difference was, in the statistical sense, eventually highly significant; but at least in the early stages of the trial the actual difference, by which I mean for instance the difference in life expectancy, amounted only to a matter of a few months, and such a 'little' difference in these circumstances was hardly sufficient to determine which treatment should be adopted. This would clearly be dependent upon other factors such as, and particularly such as, the availability of the requisite skills. We therefore elaborated the concept 'determinant' and 'determinance' to contrast with 'significant' and 'significance'. Determinance is a measure of the degree of difference between two treatments, for instance the difference in the mean survival time. Clearly the difference in effect between two treatments must be significant at whatever level of probability it is deemed suitable to apply, but if decisions are to be taken as a result of the trial then this difference must also be determinant. The level of determinance which may be preselected depends upon a number of factors such as availability of skills, expense, nature of sideeffects and the like.
I may add that, after twenty years, the last of the patients entered into the adrenalectomyhypophysectomy trial has died, and Hayward will shortly be producing a paper on these completed case histories where the figures will be highly significant and the difference clearly determinant.
I have said that when the above trial was started in 1954 these operations were performed only when every other method had been tried and had failed. In these circumstances the 'success rate' as we then defined it, a definition which I need not repeat in detail here, was just under This meant that 75 % of these very ill patients were taken from their homes and placed in hospital to undergo a series of tests culminating in a painful and frightening operation or, in the case of bilateral adrenalectomy two operations, all to no effect. This seemed to us to be a serious indictment, and we resolved upon two courses of action: the first was to see whether by advancing these operations in the treatment programme they might be more effective; the second was to search for some preoperative test which would single out those women who were more likely to benefit from these operations, so that the remainder would not be subjected to unnecessary suffering.
Immediate and Delayed Operation
In the prosecution of the first objective a trial was mounted. The subjects were patients with cancer sufficiently advanced to exclude any chance of cure by surgery, such patients who would ordinarily have received radiotherapy or hormones by administration; and to randomize them into two groups. One group would be treated immediately by adrenalectomy or hypophysectomy (the choice of operation being made by randomization as the former trial was still in operation). The other group would be treated as before by every available method short of operation, and only when these had failed were they subjected to one of the two operations of extirpation. The criterion adopted to measure the result was the period of survival from the time of randomization. Table 6 shows that no advantage accrued from advancing the time of performing either adrenalectomy or hypophysectomy and the doctor in charge may be secure in his knowledge that he is not missing the opportunity of a favourable response to these operations by first trying the effect of less formidable procedures.
Predictive Indications
The search for a preoperative test which would separate out those women likely to respond to ablative operation has been pursued with energy and success by Bulbrook and Hayward, so that it would not be proper for me to discourse on a matter in which they are so much more expert except to say that this test depends upon an analysis of the steroid hormones in the urine. Table 7 shows the substances analysed and it was found that the higher the ratio of etiocholanolone to 17-hydroxycorticosterone the better was the chance of success following either of these operations. From these findings a discriminant function was elaborated by Clive Spicer which, if positive, indicated a relatively high level of etiocholanolone in the urine and therefore was a good augury for operation and, if negative, the reverse. Other factors of predictive value are the age of the patient in relation to the menopause, and the 'free period' between the date of the definitive operation for removal of the cancer of the breast and the date of appearance of the first secondary manifestations; the longer the free period, the better the prognosis. Armed with this information we were able to construct a schema (Fig 9) CEstrogen Prednisone Cyclophosphamide cating our present practice in treating advanced cancer of the breast. Points to note are that we no longer perform adrenalectomy; that oophorectomy is to be preferred to the prescription of androgens to premenopausal patients in view of the distressing side-effects with even the least masculinizing of the androgen preparations; and that, at the time this schema was constructed, cyclophosphamide was the cytotoxin of choice. This had varied during the years and will continue to do so as less disturbing and perhaps equally, or more effective, drugs become available. At present, with the neurosurgical skills happily available to us at Guy's, the disturbance to the patient is far less following hypophysectomy than when cytotoxins are prescribed, so that the latter are reserved for the final treatment.
Transsphenoidal Hypophysectomy My colleagues Salmon and Shaheen have joined our team and a trial is in progress comparing transsphenoidal and transfrontal hypophysectomy; it looks as though transfrontal hypophysectomy may show an advantage over the transsphenoidal approach in survival rates, but this has yet to be determined. If it is shown to be so, it may be due to the fact that with both approaches small slivers of pituitary tissue are apt to be left behind. In the transfrontal approach these slivers are without blood supply, the portal circulation having been interrupted at an early stage with section of the pituitary stalk. In the transsphenoidal approach it is just that part of the pituitary attached to the stalk that may be left and, with its intact blood supply, may retain some function. On the other hand, there are some patients who are frightened of the idea of a craniotomy but will accept 'an operation through the nose'.
The Guernsey Investigation Finally, I would mention an exercise of the Breast Unit, which has been conducted by Hayward and Bulbrook: the Guernsey investigation, which arose from the incidental finding that in a group with breast cancer more women excreted low amounts of 11 deoxyoxosteroids than in a group who had not developed breast cancer. The Guernsey investigation set out to perform analysis of the urinary steroids in 5000 women on the island between the ages of 35 and 50. It is to be expected that about 150 of these women will eventually develop cancer of the breast, and 30 already have. When one of these women is found to have cancer of the breast this is reported to Bulbrook at the Imperial Cancer Research Fund and the specimen of urine taken perhaps a few years before from the woman and partly processed is finally analysed together with the urines of ten other women of the same age and parity whose urine was collected at about the same time, taken as controls. In this way it will be possible to see whether there is any specific difference in the urine of women destined to develop the clinical picture of breast cancer and, if so, when this difference can be detected in relation to the appearance of overt signs. This is a field of the greatest promise. Again the significant steroids seem to be the derivatives of the androgenic hormones, but the details of the investigation and where it is likely to lead must be left to the investigators themselves to describe.
For myself, the forty years during which I have applied myself to the problem of breast cancer have been full of interest. They have taken me into the periphery of so many fieldsbiochemistry, radiophysics, statistics and immunology; they have allowed me to forge many friendships in different scientific disciplines and they have given me the satisfaction of working with colleagues of immense skill and integrity. Above all, this is a cancer for which so much can be done for almost every sufferer, and for a significant proportion everything can be done. Every year effective methods of therapy are increasing and even at my age I hope to live to see this common malignancy pass from the care of the surgeon to that less traumatic practice of the endocrinologist, the biochemist and the immunologist.
